


COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY 10747

Dr. Feldmann's story of the deletion of the word "lincomycin" and the mention of the trade name "Clomid" apparently made quite an impression on the Subcommittee and its staff, for on page 10267 it states that Mr. Adams questioned Dr. Feldmann on these cases and was assured that they were being correctly reported.

I feel that the Subcommittee should be aware of the fact that all four of these drugs are sole source products. Since they are available only from single suppliers, I fail to see how the form of DPSC's specifications could be considered to have excluded potential competitors.

Furthermore, and contrary to the impression given in Dr. Feldmann's reported testimony, lincomycin is not a "trade name" for clindamycin. It is the official or generic name for the active ingredient in Upjohn's patented Lincocin. Clindamycin, although a related compound, is distinct and separate, with different indications. It is the generic or official name for the active ingredient in Upjohn's patented Cleocyn antibiotic. In view of the damaging inferences drawn from the misinformation presented by Dr. Feldmann, it is important that the record be corrected.

Sincerely,

  
C. Joseph Stetler

cc: Mr. John O. Adams  
Minority Counsel